The unmet need in rheumatology: Reports from the Targeted Therapies meeting 2016

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages 69-76

  Winthrop, Kevin L ^a   Strand, Vibeke ^b   Van der Heijde, Désirée ^c   Mease, Philip ^d   Crow, Mary K ^e   Weinblatt, Michael ^f   Bathon, Joan ^g   Buch, Maya H ^h   Burmester, Gerd R ⁱ   Dougados, Maxime ^j   Kay, Jonathan ^k   Mariette, Xavier ^l   Breedfeld, Ferry C ^m   Kalden, Joachim R ⁿ   Smolen, Josef S ^o   Furst, Daniel E ^p  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LEIDEN UNIVERSITY   (Netherlands)

^d UNIVERSITY OF WASHINGTON   (United States)

^e HOSPITAL FOR SPECIAL SURGERY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h Chapel Allerton Hospital   (United Kingdom)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j Hôpital Cochin ^*  (France)

^k UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^l UNIVERSITÉ PARIS SACLAY   (France)

^m LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^o Vienna Medical Faculty   (Austria)

^p UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Ankylosing spondylitis; Lupus; Psoriatic arthritis; Rheumatoid arthritis; Spondyloarthritis; Systemic sclerosis

Indexed keywords

DENOSUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

ANKYLOSING SPONDYLITIS; ARTICLE; COMORBIDITY; CONNECTIVE TISSUE DISEASE; DACTYLITIS; ENTHESITIS; HUMAN; IMMUNOGLOBULIN G4 RELATED DISEASE; MOLECULARLY TARGETED THERAPY; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SPONDYLARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VASCULITIS; ANIMAL; DISEASE COURSE; HEALTH CARE PLANNING; IMMUNOLOGY; MEDICAL RESEARCH; METHODOLOGY; NEEDS ASSESSMENT; REMISSION; RHEUMATIC DISEASES; RHEUMATOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIRHEUMATIC AGENTS; BIOMEDICAL RESEARCH; DISEASE PROGRESSION; HEALTH PRIORITIES; HUMANS; MOLECULAR TARGETED THERAPY; NEEDS ASSESSMENT; REMISSION INDUCTION; RESEARCH DESIGN; RHEUMATIC DISEASES; RHEUMATOLOGY; TREATMENT OUTCOME;

EID: 84984831696     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. FURST DE, KEYSTONE EC, SO AK et al.: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013; 72 (Suppl. 2): ii2-34.
2. SMOLEN JS, LANDEWé R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
3. SINGH JA, SAAG KG, BRIDGES SL Jr, et al.: 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 2016; 68: 1-25.
4. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
5. COOK MJ, DIFFIN J, SCIRÈ CA et al.: Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology 2016 May 24. pii: kew210. [Epub ahead of print].
6. HOPSON S, SAVERNO K, LIU LZ et al.: Impact of out-of-pocket costs on prescription fills among new initiators of biologic therapies for rheumatoid arthritis. J Manag Care Spec Pharm 2016; 22: 122-30.
7. FERRIOLS-LISART R, FERRIOLS-LISART F: Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under realworld settings: a systematic review. Rheumatol Int 2015; 35: 1193-210.
8. KIELY PD: Biologic efficacy optimization-a step towards personalized medicine. Rheumatology 2016; 55: 780-8.
9. van der MEULEN TA, HARMSEN HJ, BOOTSMA H, SPIJKERVET FK, KROESE FG, VISSINK A: The microbiome systemic diseases connection. Oral Dis 2016 Mar 8. [Epub ahead of print].
10. MARENZANA M, Vande VELDE G: Refine, reduce, replace: Imaging of fibrosis and arthritis in animal models. Best Pract Res Clin Rheumatol 2015;. 29: 715-40.
11. HAROON M, FITZGERALD O: Psoriatic arthritis: complexities, comorbidities and implications for the clinic. Expert Rev Clin Immunol 2016; 12: 405-16.
12. SUKHOV A, ADAMOPOULOS IE, MAVERAKIS E: Interactions of the immune system with skin and bone tissue in psoriatic arthritis: a comprehensive review. Clin Rev Allergy Immunol, 2016 Jan 16 [Epub ahead of print].
13. BARNAS JL, RITCHLIN CT: Etiology and pathogenesis of psoriatic arthritis. Rheum Dis Clin North Am 2015; 41: 643-63.
14. MEASE PJ, ARMSTRONG AW: Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 2014; 74: 423-41.
15. MEASE PJ: Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/ Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res 2011; 63 (Suppl 11): S64-85.
16. GILL T, ASQUITH M, ROSENBAUM JT, COLBERT RA: The intestinal microbiome in spondyloarthritis. Curr Opin Rheumatol 2015; 27: 319-25.
17. OGDIE A, SCHWARTZMAN S, HUSNI ME: Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 2015; 27: 118-26.
18. DOUGADOS M, BAETEN D: Spondyloarthritis. Lancet 2011; 377: 2127-37.
19. BERTEAU JP, MIELKE G, MORLOCK MM, HUBER G: Morphological and biomechanical analyses of the subchondral mineralized zone in human sacral facet joints: Application to improved diagnosis of osteoarthritis. Clin Anat 2015; 28: 538-44.
20. GOEKOOP-RUITERMAN YP1, DE VRIESBOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
21. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
22. MAHAJAN A, HERRMANN M, MUNOZ LE: Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE. Front Immunol 2016; 7: 35.
23. WU YW, TANG W, ZUO JP: Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol Sin 2015; 36: 1395-407.
24. JORDAN N, D'CRUZ D: Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications. Ther Adv Musculoskelet Dis 2015; 7: 234-46.
25. BLANCO P, UENO H, N SCHMITT N: T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis. Eur J Immunol 2016; 46: 281-90.
26. WU H, ZHAO M, YOSHIMURA A, CHANG C, LU Q: Critical link between epigenetics and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol, 2016; 50: 333-44.
27. REDDY V, JAYNE D, CLOSE D, ISENBERG D: B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 2013; 15 (Suppl. 1): S2.
28. FURIE R., TODER K, ZAPANTIS E: Lessons learned from the clinical trials of novel biologics and small molecules in lupus nephritis. Semin Nephrol 2015; 35: 509-20.
29. MOALLEM E, KOREN E, ULMANSKY R et al.: A liposomal steroid nano-drug for treating systemic lupus erythematosus. Lupus 2016 Mar 7. [Epub ahead of print].
30. MAHIEU M, YOUNT S, RAMSEY-GOLDMAN R: Patient-Reported Outcomes in Systemic Lupus Erythematosus. Rheum Dis Clin North Am 2016; 42: 253-63.
31. STASI R: An overview of pharmacotherapy for anti-neutrophil cytoplasmic antibodyassociated vasculitis. Drugs Today 2010; 46: 919-28.
32. FLINT SM, MCKINNEY EF, SMITH KG: Emerging concepts in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Rheumatol 2015; 27: 97-203.
33. TOMASSON G: Outcome measures for antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Rheumatol 2015; 27: 38-44.
34. AYDIN SZ, MERKEL PA, DIRESKENELI H: Outcome measures for Takayasu's arteritis. Curr Opin Rheumatol 2015; 27: 32-7.
35. ADLER S, KUCHEN S, WERMELINGER F, DAN D, VILLIGER PM, SEITZ M: Tocilizumab for the treatment of giant cell arteritis - a randomized placebo-controlled trial (abstract). Arthritis Rheumatol 2015; 67 (Suppl. 10).
36. HAO M, LIU M, FAN G, YANG X, LI J: Diagnostic value of serum IgG4 for IgG4-related Disease: A PRISMA-compliant systematic review and meta-analysis. Medicine 2016; 95: e3785.
37. SEKIGUCHI H, HORIE R, KANAI M, SUZUKI R, YI ES, RYU JH: Immunoglobulin G4-related disease: retrospective analysis of 166 patients. Arthritis Rheumatol 2016 Mar 18.